• Oncotelic Therapeutics completed a triangular merger on May 1, 2026 that transferred Neurobridge IP Holdings into a Lunai Bioworks subsidiary, leaving the subsidiary as a wholly owned unit of Lunai.
• Consideration consisted of 8 shares of newly designated Series B Convertible Preferred Stock with aggregate stated value of $20 million, split 5 shares with stated value of $12.5 million to Oncotelic unit and 3 shares with stated value of $7.5 million to Pelerin Therapeutics.
• Neurobridge IP Holdings held only a multi-jurisdictional patent portfolio at closing, with no operating business, employees, customers, or material liabilities.
• An IP assignment agreement dated April 27, 2026 provided for contribution of Oncotelic intellectual property assets into Neurobridge IP Holdings ahead of the merger.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncotelic Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-021306), on May 05, 2026, and is solely responsible for the information contained therein.